Panasonic utökar sin tillverkningskapacitet för värmepumpar i Tjeckien
Panasonics fabrik i tjeckiska Pilsen startade sin produktion av luft-vattenvärmepumpar för tre år sedan. Produktionen har stadigt ökat, delvis tack vare ökad efterfrågan på dess luft/vattenvärmepumpslösningar, Aquarea.
Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20220408005445/sv/
Panasonic is increasing its heat pump production for Europe (Photo: Business Wire)
Enligt European Heat Pump Market and Statistics Report (den statistiska rapporten om den europeiska marknaden för värmepumpar), som innehåller data från 21 europeiska länder, ökade försäljningen av värmepumpar med 7,4 procent i Europa under 2020. Det innebar 1,62 miljoner sålda enheter och ett nytt försäljningsrekord trots pandemin. Sedan Panasonic startade produktionen av värmepumpar i Pilsenfabriken under 2018 har kapaciteten kontinuerligt vuxit, för att möta såväl den aktuella efterfrågan som en snabbare framtida tillväxt i Europa.
Värmepumparna står för en årlig minskning av koldioxidutsläppen inom EU med 9,16 miljoner ton och enligt Internationella energirådet skulle värmepumpar kunna spara 1,8 miljoner ton koldioxid per år inom bygg- och industrisektorerna. Enrique Vilamitjana, vd för Panasonic HVAC Europe, förklarar: “Värmepumpstekniken har varit efterfrågad i Europa under flera års tid, men nu ser vi att den verkligen börjar ta fart. Det är en region med stor medvetenhet kring klimatförändringarna och en stark vilja att förnya och bygga miljövänliga hem. Av den anledningen kommer våra produkter för uppvärmning och kylning att fortsätta motivera konsumenter och tillverkare att reducera sina koldioxidavtryck. Tillsammans med vår tyska FoU-enhet med inriktning på VVS-teknik har vi möjlighet att både designa och producera värmepumpar som uppfyller våra europeiska kunders krav.”
Om Panasonickoncernen
För mer information om Panasonickoncernen kan du besöka : https://holdings.panasonic/global/
För att se det här innehållet från cts.businesswire.com måste du ge ditt medgivande sidans topp.
Se källversionen på businesswire.com: https://www.businesswire.com/news/home/20220408005445/sv/
Contact information
Presskontakt :
Panasonic Europe, Corporate Communications
Tanya Houston
tanya.houston@wildwoodpr.com
Om
Följ Business Wire
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.
Besök vårt pressrum